RECORDATI INDUSTRIA CHIMICA (REC.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:REC - IT0003828271 - Common Stock
REC.MI Key Statistics, Chart & Performance
The current stock price of REC.MI is 47.84 EUR. In the past month the price decreased by -11.58%. In the past year, price decreased by -6.69%.
REC.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SAN.PA | SANOFI | 10.93 | 201.73B | ||
| SNW.DE | SANOFI | 10.85 | 200.34B | ||
| 1SAN.MI | SANOFI | 10.85 | 200.32B | ||
| MRK.DE | MERCK KGAA | 13.98 | 51.85B | ||
| UNC.DE | UCB SA | 37.74 | 47.13B | ||
| UCB.BR | UCB SA | 37.18 | 46.43B | ||
| BAYN.DE | BAYER AG-REG | 6.81 | 35.75B | ||
| 1BAYN.MI | BAYER AG-REG | 6.78 | 35.58B | ||
| IPN.PA | IPSEN | 11.83 | 10.18B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 102.4 | 9.48B | ||
| VIRP.PA | VIRBAC SA | 19.61 | 2.85B | ||
| DMP.DE | DERMAPHARM HOLDING SE | 17.58 | 2.04B |
Related stock screener links
About REC.MI
Company Profile
Recordati SpA engages in the research, development, manufacture, and marketing of pharmaceuticals. The company is headquartered in Milan, Milano and currently employs 4,583 full-time employees. The company promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The firm is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. The company operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The firm owns and operates through Natural Point srl also in the food supplement sector.
Company Info
RECORDATI INDUSTRIA CHIMICA
Via Matteo Civitali, 1
Milan MILANO IT
Employees: 4539
Phone: 3902487871
RECORDATI INDUSTRIA CHIMICA / REC.MI FAQ
What does RECORDATI INDUSTRIA CHIMICA do?
Recordati SpA engages in the research, development, manufacture, and marketing of pharmaceuticals. The company is headquartered in Milan, Milano and currently employs 4,583 full-time employees. The company promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The firm is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. The company operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The firm owns and operates through Natural Point srl also in the food supplement sector.
What is the current price of REC stock?
The current stock price of REC.MI is 47.84 EUR. The price increased by 1.23% in the last trading session.
Does RECORDATI INDUSTRIA CHIMICA pay dividends?
RECORDATI INDUSTRIA CHIMICA (REC.MI) has a dividend yield of 2.6%. The yearly dividend amount is currently 1.23.
What is the ChartMill rating of RECORDATI INDUSTRIA CHIMICA stock?
REC.MI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is RECORDATI INDUSTRIA CHIMICA worth?
RECORDATI INDUSTRIA CHIMICA (REC.MI) has a market capitalization of 10.00B EUR. This makes REC.MI a Large Cap stock.
Can you provide the ownership details for REC stock?
You can find the ownership structure of RECORDATI INDUSTRIA CHIMICA (REC.MI) on the Ownership tab.
REC.MI Technical Analysis
REC.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to REC.MI. While REC.MI is still in line with the averages on profitability rating, there are concerns on its financial health.
REC.MI Financial Highlights
Over the last trailing twelve months REC.MI reported a non-GAAP Earnings per Share(EPS) of 1.97. The EPS increased by 10.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.42% | ||
| ROA | 7.87% | ||
| ROE | 21.77% | ||
| Debt/Equity | 1.16 |
REC.MI Forecast & Estimates
15 analysts have analysed REC.MI and the average price target is 61.06 EUR. This implies a price increase of 27.64% is expected in the next year compared to the current price of 47.84.
For the next year, analysts expect an EPS growth of 2.94% and a revenue growth 12.87% for REC.MI